ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RDHL Redhill Biopharma Ltd

0.525
-0.0124 (-2.31%)
Last Updated: 13:46:05
Delayed by 15 minutes

Period:

Draw Mode:

Volume 309,626
Bid Price 0.5206
Ask Price 0.525
News -
Company Name Stock Ticker Symbol Market Type
Redhill Biopharma Ltd RDHL NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-0.0124 -2.31% 0.525 13:46:05
Open Price Low Price High Price Close Price Prev Close
0.5322 0.52 0.5374 0.5374
Trades Volume VWAP Dollar Volume Avg Volume
967 309,626  0.524722  162,468 -
Last Trade Time Type Quantity Stock Price Currency
13:46:05 115  0.525 USD

Redhill Biopharma Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 0.00 - 61.8M -71.67M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Redhill Biopharma

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RDHL Message Board. Create One! See More Posts on RDHL Message Board See More Message Board Posts

RDHL Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Your Recent History

Delayed Upgrade Clock